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Teenage exercise is associated
with earlier symptom onset in
dysferlinopathy: a retrospective
cohort study
Introduction

Dysferlinopathy, an autosomal recessive muscular dystrophy caused by DYSF
mutations, demonstrates a variable phenotype and progression rate, with symptom
onset ranging from first to eighth decade
and some patients requiring wheelchairs
for mobility within 10 years, with others
remaining minimally affected.1
Dysferlinopathy
populations
have
previously been described as having an
unusually high level of presymptomatic
sporting ability.2 We hypothesised that
this activity could be related to subsequent disease progression and investigated the hypothesis using data from
the Jain Foundation’s Clinical Outcomes

Data were used from 182 of the 202
patients enrolled in the Jain COS; 10
dropped out and did not give permission to use their data and 10 did not fully
complete the exercise questionnaire.
The questionnaire used in the screening
visits (online supplementary information) between 6 November 2012 and 19
March 2015 asked about the type, level
and frequency of all physical activity prior
to symptom onset. Self-reported age of
first symptoms, first wheelchair use and
full-time wheelchair use was taken from
screening questionnaires.
Exercises were classified based on metabolic equivalents (METs) as moderate
(MET 3–6) or vigorous (MET >6) (online
supplementary table 1).3 Participants were
coded, based on the maximum frequency
of activity reported between ages 10 and
18 years, as 0—no physical activity; 1—
vigorous activity occasionally/monthly,
or moderate activity once weekly; 2—
moderate activity multiple times per week
or vigorous activity once weekly; and 3—
vigorous activity multiple times per week.

Statistical analysis

Age of symptom onset was compared by
analysis of variance (ANOVA) with least
squares means for individual group differences. Risk of symptom onset, occasional
wheelchair use and full-time wheelchair
requirement over time were compared for
exercise groups 1, 2 and 3 against group
0 using Cox proportional hazards regression. Proportional hazards assumption
was violated for initial wheelchair use.

Inspection of survival curves suggested
this was occurring at later ages; thus, analysis was rerun censoring at age 50 if there
was no wheelchair use up to that point,
which prevented violation of this assumption while capturing 46/55 events.
Interaction between teen exercise level,
gender and clinical diagnosis was also
assessed by two-way ANOVA. Subgroups
of limb girdle muscular dystrophy 2B
(LGMD2B), Miyoshi myopathy (MM) or
‘other’ (all genetically confirmed dysferlinopathies) were used for analysis.

Results

Exercise group 0 had more female patients
(65%). Demographic characteristics of
each exercise group were otherwise similar
(online supplementary table 2).

Age of symptom onset

Estimated mean age of symptom onset
differed by group (P=0.03) and was later
in group 0 (mean 24.8 (95% CI 22.3 to
27.2)) compared with groups 2 (20.2 (18.1
to 22.3), P=0.006) and 3 (20.6 (18.4 to
22.8), P=0.01), but not 1 (21.7 (17.7 to
25.7), P=0.20). Cox regression analysis
suggested that groups 2 (HR 1.56 (95%
CI 1.06 to 2.30)) and 3 (HR 1.54 (1.04
to 2.30)) were at increased risk of earlier
symptom onset than group 0 (figure 1).
This was not significant for group 1 (HR
1.38 (0.78 to 2.45)).
In patients with a clinical diagnosis
of LGMD2B, groups 1–3 all showed a
significantly increased risk of earlier onset
compared with group 0 (1: HR 7.74 (95%
CI 3.07 to 19.49); 2: HR 1.71 (1.05 to
2.77); 3: HR 1.91 (1.14 to 3.18)). Significant associations were not seen among those
with a diagnosis of MM or ‘other’.

Figure 1 Risk of symptomatic disease and wheelchair use over time in dysferlinopathy. Graphs show the probability of remaining event free during the
time under study using Cox proportional hazards regression. Events are the onset of symptoms (A), the first time a wheelchair is used (B) and the need to
use a wheelchair full time (C). Survival probabilities significantly different from exercise group 0 are marked with an asterisk (*). For first-time wheelchair
use (B), this graph shows the results excluding those patients over 50 years of age at the screening visit as including these patients led to a violation of the
proportional hazards assumption.
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Results were independent of gender,
which was not significantly related to
age of onset (P=0.329) or exercise group
(P=0.328).

Wheelchair use

Fifty-five patients reported age at first
wheelchair use and 42 using a wheelchair
full time.
Statistical analysis showed a higher
risk for part-time wheelchair use in exercise groups 2 (HR 3.57 (95% CI 1.36 to
9.36)) and 3 (HR 5.44 (2.20 to 13.48))
compared with group 0; no association
was noted for group 1 (HR 2.12 (0.53 to
8.51)).
Greater teenage activity was also associated with increased risk of full-time
wheelchair requirement in group 3 (HR
4.11 (1.75 to 9.64)). This was not significant in groups 1 (HR 0.97 (0.20 to 4.73))
or 2 (HR 2.18 (0.82 to 5.75)).

Discussion

In the present study, patients recalling
greater teenage exercise levels demonstrated
increased risk for earlier symptom onset and
wheelchair requirement. Teenage exercise
level was chosen as this is typically before
symptom onset in dysferlinopathy, yet old
enough for significant exercise regimens
to have started. Although an association
between exercise and subsequent disease
progression has previously been suggested
by Angelini et al4 Klinge et al2 reported
no significant effect of exercise on age of
symptom onset in 36, mostly LGMD2B,
patients. These studies all rely on patient
recall, introducing potential question and
recall bias. We tried to mitigate for this
using a scoring system based on METs
rather than Klinge’s use of patient-reported
sporting level. However, our approach still
does not produce uniform exercise categories, requiring grouping of different types
and frequencies of exercise, which may not
have equitable physiological impact. Unfortunately, this is the nature of a retrospective study, which is necessary while so few
patients are diagnosed presymptomatically.
Exercise is usually considered beneficial
in muscular dystrophies, and so this finding
in dysferlinopathy may suggest a unique
underlying pathological mechanism. Investigation of this was not within the scope
of this study. However, previous work has
suggested that dysferlinopathy may increase
aptitude for training early in life, but the
more a patient exercises vigorously, the
more muscle damage occurs, which is then
inadequately repaired5—accelerating both
disease onset and symptom progression.

This study raises implications for
patients and families. If intensive exercise
causes earlier onset and faster progression,
asymptomatic patients should consider
limiting their exercise and affected siblings
should be identified to allow for early
disease-modifying advice. However, as the
HRs are small, this needs to be balanced
against the loss of other lifestyle benefits
of exercise. As we did not look at the
effects of exercise once symptoms began,
we would not advocate that symptomatic
patients stop exercising.
This letter describes an association of
intensive exercise during the teenage years
with earlier disease onset and faster rate
of disease progression in patients with
dysferlinopathy.
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